Objective To investigate the effect of Platelet-activating factor(PAF)in pathogenesy of asthma in high altitude Methods ELISA and other methods were used to detect the quantity of platelet(PLT)and the level of serum platelet-activating factor(PAF)in the plain control group、the plateau control group and the plateau asthma patients group.Results The quantity of PLT in plain control group and plateau control group were significantly lower than that of plateau asthma patients group.(P

Objective To observe the effect of lentivirus vector-medicated enhanced green fluorescence protein (EGFP) transfection on in vitro corneal epithelial cells.Methods Primary corneal epithelial cells of rabbits were cultured and transfected with lentivirus vector into different multiplicity of infection (MOI) in order to find the best transfection dose.After 24,48,72,and 96 h of transfection,expression of EGFP was observed under microscope and detected by RT-PCR.The transfection rate of corneal epithelial cells was calculated in different MOI.Results EGFP was expressed in corneal epithelial cells 48 h after transfection,which increased with the increasing transfection time.The transfection rate of corneal epithelial cells was 4.5%?0.6%,30.4%?0.9%,51.9%?1.4%,and 75.4%?0.7%,respectively,when MOI was 1,10,50,and 100(P

Objective To discuss the cause, managment and prevention of the postoperative complications of orbital implantation by clinical case analysis, and to provide reference for the future clinical work. Methods 175 cases of orbital implantation from Aug. 2011 to Aug. 2013 were retrospectively analyzed in our department. The postoperative complications occurrence, related symptomatic treatment, and the reasons of complications were analyzed. Results Complications occurred in 175 cases of 9 cases(5. 14%),including 4 cases of the con-junctival cyst (2.29%),3 cases of orbital implants exposure(1.71%),1 case of orbital chronic infection(0.57%)and 1 case of subcon-junctival tissue atrophy(0. 57%). All of them had obtained good curative through cyst excision or orbital implanting again after the active treatment. There were no complication occurred again. Conclusion The postoperative complications should be positively analyzed, and early positive precaution could reduce most of the complications.

The experiment was designed to study the mechanism of increasing efficiency of Ligustrum lucidum steamed with wine. Rats in vivo with gastrointestinal perfusion model were used. The contents of salidroside and specnuezhenide in the fluid of gastrointestinal perfusion of rats were measured by HPLC at different time points after dosing. Then the K(a) and absorption percentage were calculated. Specnuezhenide could be detected in the fluid of gastrointestinal perfusion of specnuezhenide. The K(a) of the specnuezhenide and salidroside in the fetal intestines are 0.055 3 and 0.144 2 h(-1) respectively and the total absorptivity are 24.46% and 60.14% respectively after 4 hours. The K(a) in the stomach are 5.70 and 8.26 h(-1) respectively and the total absorptivity are 34.21% and 47.23% respectively after 4 hours. The experiment proved that specnuezhenide can be metabolized into salidroside which is more beneficial for gastrointestinal absorption. The experiment proved that specnuezhenide can be metabolized into salidroside both in the rat's stomach and the fetal intestine and compared with the specnuezhenide salidroside is more conducive to gastrointestinal absorption. The results suggested that the increasing efficiency on liver and kidney of L. lucidum steamed with wine has business with the fact that Specnuezhe nide is more conducive to the body after it is changed into salidroside.
Animals ; Chemistry, Pharmaceutical ; Gastrointestinal Tract ; metabolism ; Glucosides ; chemistry ; metabolism ; Intestinal Absorption ; Male ; Phenols ; chemistry ; Pyrans ; chemistry ; metabolism ; Rats ; Rats, Sprague-Dawley

Objective To explore the influence of cyclosporin on C-reactive protein (CRP),transforming growth factor-?1( TGF- ?1), matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in rats with asthma. Methods Eighty SD rats were randomly divided into normal group, model group, dexamethasone group,low- dose and high-dose of cyclosporin groups. The changes of CRP, TGF-?1, MMPs and TIMPs in samples were measured by computerized image analysis system.Results The contents of CRP, TGF-?1, MMPs and TIMPs in model group were significantly higher than those of control group(all P0.05).Conclusion CRP,TGF-?1,MMPs and TIMPs are related to asthma and certain dose of cyclosporin is similar to hormone.

Conjunctiva ; surgery ; Diagnosis, Differential ; Eye Neoplasms ; metabolism ; pathology ; surgery ; Humans ; Infant ; Male ; Neoplasm Recurrence, Local ; Nerve Sheath Neoplasms ; metabolism ; pathology ; surgery ; Reoperation ; S100 Proteins ; metabolism

Programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors are a novel kind of immune checkpoint blockers, which are the highlights of anti-tumor immune therapy. PD-1 inhibitors, such as nivolumab and pembrolizumab have been granted by the market authorization to treat melanoma and non-small cell lung cancer. Clinical trials of their efficacy and safety on renal cell carcinoma, bladder carcinoma and Hodgkin′s lymphoma are still in process. PD-L1 inhibitors atezolizumab, durvalumab and avelumab have been approved by FDA for treatment of urothelial carcinoma. Several other drugs are in phase I clinical trials. This paper gives a brief summary of recent advances in the studies on PD-1/PD-L1 inhibitors.

The Pharmacopoeia of the People’s Republic of China 2025 edition is to be issued in March 2025. Chinese Pharmacopoeia is the basic requirements on the drug manufacture, drug testing, drug use and drug administration. The new edition Chinese Pharmacopoeia will be dramatically improved on the pharmacopoeia monographs included, establishing the standards system, standards conversion and application of drug quality control for the new technology, new method & new tool, drug control on the safety and effectiveness as well as the drug standard international harmonization. It will take important role on improving the drug quality, ensuring the safety of drugs for public use, strengthen technical support for drug administration, promoting the high-quality development of China’s medical and pharmaceutical industry. This paper introduces the development and revision of the Chinese Pharmacopoeia 2025 Edition,aim at helping the industries well understanding and implantation the new edition Chinese Pharmacopoeia.

Adult ; Antigens, CD20 ; metabolism ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; CD79 Antigens ; metabolism ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; metabolism ; pathology ; Male ; PAX5 Transcription Factor ; metabolism ; Young Adult

BACKGROUND: Age-related macular degeneration is a condition that leads to the deterioration of the macula in the elderly, and is characterized by the presence of drusen and degenerative changes of the retinal pigment epithelium and choroidal capillaries. It is a major cause of blindness worldwide. The commonly used strategies, including antioxidant therapy and dilation of blood vessels, have shown undesired outcomes in clinical practice. Ranibizumab, an anti-vascular endothelial growth factor fusion protein, is an angiogenesis inhibitor that has been used to treat wet (neovascular) age-related macular degeneration; however, patients treated with ranibizumab are prone to develop endophthalmitis, rhegmatogenous retinal detachment, retinal tears, and iatrogenic traumatic cataract. OJECTIVE: To determine the efficacy and safety of intravitreal injection of combination of triamcinolone acetonide and ranibizumab in the treatment of age-related macular degeneration in a randomized controlled trial. METHODS: Eighty patients (160 eyes) with age-related macular degeneration admitted at Jingzhou Hospital Affiliated to Tongji Medical School of Huazhong University of Science and Technology, China will be recruited. These patients will be randomly assigned to control or treatment group at a 1:1 ratio. The patients in the control group will be treated with intravitreal injection of triamcinolone acetonide (0.1 mL, once daily), while those in the treatment group will be treated with combined intravitreal injection of triamcinolone acetonide (0.025 mL, once daily) and ranibizumab (0.05 mL, once a month). All patients will undergo continuous treatment for 3 months, followed by a 6-month follow-up. The primary outcome measure is foveal retinal thickness before and 6 months after treatment. The secondary outcome measures include best corrected visual acuity, intraocular pressure, quality of life scores before and 6 months after treatment, and the incidence of adverse events at 6 months after treatment. This study was approved by the Ethics Committee of the Jingzhou Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, China (approval No. 20170338), and will be performed in accordance with the Declaration of Helsinki. The participants will be informed of the study protocol and procedures and asked to sign an informed consent. Participant recruitment will be initiated in January 2018. Sample and data collection will begin in January 2018 and end in June 2018. The analysis of outcome measures and the completion of trial will be in September 2018. The results of this study will be disseminated through presentations at scientific meetings and/or by publication in peer-reviewed journals. This trial was registered with the Chinese Clinical Trial Registry (registration No. ChiCTR-IOR-17013865). DISCUSSION: We aim to confirm the safety and efficacy of the intravitreal injection of combination of triamcinolone acetonide and ranibizumab in the treatment of age-related macular degeneration.